AC Immune (ACIU)
(Delayed Data from NSDQ)
$3.69 USD
0.00 (0.00%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.67 -0.02 (-0.54%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum D VGM
Cash flow Statements
Fiscal Year End for AC Immune falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -60.41 | -74.14 | -79.86 | -66.04 | 45.74 |
Depreciation/Amortization & Depletion | 2.47 | 2.47 | 2.63 | 2.10 | 1.28 |
Net Change from Assets/Liabilities | -16.89 | -8.84 | 7.48 | -4.88 | 5.69 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.56 | 3.41 | -2.12 | 5.34 | 2.87 |
Net Cash From Operating Activities | -67.29 | -77.09 | -71.87 | -63.48 | 55.58 |
Property & Equipment | -0.89 | -1.30 | -2.88 | -1.75 | -1.90 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 74.01 | 26.20 | -55.80 | 32.00 | -65.42 |
Other Investing Activities | 0.00 | 0.00 | -0.03 | -0.03 | 0.00 |
Net Cash from Investing Activities | 73.12 | 24.90 | -58.71 | 30.22 | -67.32 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 48.79 | 0.00 | 19.48 | 0.15 | 0.07 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 25.67 | 0.00 | 50.81 |
Increase (Decrease) Short-Term Debt | -0.61 | -0.60 | -0.56 | -1.01 | -0.42 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -0.81 | -0.01 | 0.00 | -0.51 |
Net Cash from Financing Activities | 48.18 | -1.41 | 44.58 | -0.86 | 49.94 |
Effect of Exchange Rate Changes | -1.76 | 0.55 | -0.08 | -0.75 | -0.83 |
Net Change In Cash & Equivalents | 52.25 | -53.06 | -86.08 | -34.87 | 37.37 |
Cash at Beginning of Period | 35.18 | 86.15 | 176.03 | 206.48 | 157.48 |
Cash at End of Period | 87.43 | 33.10 | 89.95 | 171.61 | 194.85 |
Diluted Net EPS | -0.71 | -0.89 | -1.06 | -0.92 | 0.64 |
Fiscal Year End for AC Immune falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -44.92 | -20.42 | -60.41 | -56.01 | -38.21 |
Depreciation/Amortization & Depletion | 1.22 | 0.64 | 2.47 | 1.88 | 1.24 |
Net Change from Assets/Liabilities | 120.89 | 20.70 | -16.89 | -0.61 | -1.12 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.68 | 0.25 | 7.56 | 4.70 | 3.70 |
Net Cash From Operating Activities | 81.88 | 1.17 | -67.29 | -50.04 | -34.39 |
Property & Equipment | -0.35 | -0.28 | -0.89 | -0.72 | -0.39 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -109.47 | -26.59 | 74.01 | 48.67 | 42.27 |
Other Investing Activities | -0.06 | -0.06 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -109.88 | -26.93 | 73.12 | 47.95 | 41.88 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.15 | 0.00 | 48.79 | 2.98 | 2.27 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -0.38 | -0.19 | -0.61 | -0.46 | -0.30 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.60 | -0.60 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -0.83 | -0.79 | 48.18 | 2.51 | 1.97 |
Effect of Exchange Rate Changes | -0.94 | 1.99 | -1.76 | -0.03 | -0.09 |
Net Change In Cash & Equivalents | -29.78 | -24.56 | 52.25 | 0.39 | 9.37 |
Cash at Beginning of Period | 86.79 | 89.73 | 35.18 | 35.75 | 35.14 |
Cash at End of Period | 57.01 | 65.17 | 87.43 | 36.13 | 44.50 |
Diluted Net EPS | -0.25 | -0.21 | -0.06 | -0.20 | -0.22 |